Invention Grant
- Patent Title: Regulatable chimeric antigen receptor
-
Application No.: US15105074Application Date: 2014-12-19
-
Publication No.: US10287354B2Publication Date: 2019-05-14
- Inventor: Jennifer Brogdon , Boris Engels , David Jonathan Glass , Brian Granda , John Hastewell , Andreas Loew , Joan Mannick , Michael Milone , Leon Murphy , William Raj Sellers , Huijuan Song , Brian Edward Vash , Jan Weiler , Qilong Wu , Li Zhou
- Applicant: Novartis AG , The Trustees of the University of Pennsylvania
- Applicant Address: CH Basel US PA Philadelphia
- Assignee: Novartis AG,The Trustees of the University of Pennsylvania
- Current Assignee: Novartis AG,The Trustees of the University of Pennsylvania
- Current Assignee Address: CH Basel US PA Philadelphia
- Agency: Lando & Anastasi, LLP
- Priority: WOPCT/CN2014/082615 20140721; WOPCT/CN2014/090494 20141106
- International Application: PCT/CN2014/094383 WO 20141219
- International Announcement: WO2015/090229 WO 20150625
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K31/436 ; A61K35/17 ; C07K14/705 ; C07K14/71 ; C07K14/725 ; C12N9/90 ; C07K14/74

Abstract:
Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
Public/Granted literature
- US20160311907A1 REGULATABLE CHIMERIC ANTIGEN RECEPTOR Public/Granted day:2016-10-27
Information query